Which Pot Stock ETF Should You Buy?

A new pot stock ETF launched last month, bringing the total number of marijuana funds up to 10. A new pot stock ETF launched last month, bringing the total number of marijuana funds up to 10. Which one is right for you? Today, Wealth Daily contributor Samuel Taube is digging into the differences between them… You are receiving this email because you subscribed to Wealth Daily. [Click here]( to manage your e-mail preferences. [Wealth Daily logo] Which Pot Stock ETF Should You Buy? [Samuel Taube Photo] By [Samuel Taube]( Written Nov. 03, 2019 Last month — on September 19, to be exact — exchange-traded fund (ETF) issuer Global X ETFs launched the Global X Cannabis ETF (NASDAQ: POTX). This latest addition to the pot stock ETF universe tracks a largely Canadian portfolio of marijuana-related companies. Its top holdings include Toronto-listed growers like Canopy Growth Corp. (TSX: WEED) and Aphria (TSX: APHA), as well as pharmaceutical companies involved in the medical marijuana industry like GW Pharmaceuticals (NASDAQ: GWPH). If you’ve been following pot stocks for a while, this ETF concept might sound familiar. And that’s because it’s not exactly new at this point. POTX isn’t the first pot stock ETF — or the second, or even the fifth. It’s actually the tenth to hit the markets and the fourth launch of its kind this year. Now that these popular funds number in the double digits, it’s getting difficult to tell them apart. After all, the marijuana industry is still relatively young, and many funds contain similar sets of holdings. Today, we’re going to profile each of the 10 pot stock ETFs on the market today — revealing their holdings, volumes, expense ratios, and more — so you can pick the fund that’s right for you. Mark Your Calendar: November 13, 2019 That’s the day everything will change... A stunning new technology will be announced... It’s already garnered the interest — and investment — of billionaires like Larry Ellison, Peter Thiel, and Jeff Bezos. Some of the largest institutions on the planet are in, too... - Fidelity - Blackrock - Vanguard - JP Morgan You owe it to yourself to at least take a look... The course of human history will once again shift. This is your chance to make a mint in the process. [Click here now for the full report.]( ETFMG Alternative Harvest ETF (NYSE: MJ) MJ is the oldest and largest ETF on the market today. It started trading back in 2015 — an eternity ago in pot stock time — and has $771.72 million in assets under management (AUM) at the time of writing. The fund’s holdings are a fairly standard mix of growers and medical companies — its top three positions are GW Pharmaceuticals, Cronos Group (TSX: CRON), and Canopy Growth Corp. It has an expense ratio of 0.75%. MJ currently pays a hefty 4.95% dividend and trades at a 0.19% discount to its net asset value (NAV). 766,431 shares have changed hands in the last month, making MJ the most liquid pot stock ETF. Horizons Marijuana Life Sciences ETF (TSX: HMMJ) HMMJ is the second-largest and second-oldest pot stock ETF on the market. It started trading in the spring of 2017 and has $504.98 million in AUM. Although the ETF’s name implies a medical focus, HMMJ is actually largely invested in Canadian producers of recreational pot. Its top three holdings are Canopy Growth, Cronos, and Aurora Cannabis (TSX: ACB). It charges a relatively high expense ratio of 0.86%. However, HMMJ pays a whopping 10.71% dividend at the time of writing. It trades for a 0.27% premium to NAV and is one of the more liquid ETFs on this list. 367,305 shares have been traded in the last month. AdvisorShares Pure Cannabis ETF (NYSE: YOLO) This ETF’s ticker symbol is a reference to a meme — You Only Live Once, or YOLO — which died out years ago among the general public but lives on in the world of online investment forums as a euphemism for a high-risk, high-return stock purchase. This marketing strategy has clearly worked to some extent. YOLO is the third-largest pot stock ETF out there, with $47.29 million in AUM as of late October. Its holdings are slightly less Canadian than most of the other funds here (though it still has a substantial allocation to the Great White North). Its top three positions are Village Farms International (TSX: VFF), Trulieve Cannabis (OTC: TCNNF), and GW Pharmaceuticals. Its expense ratio of 0.74% almost seems like it was chosen specifically to undercut MJ. YOLO currently pays a 1.97% dividend and trades for a 0.80% premium to NAV. It has seen 57,314 shares change hands in the last month. The Cannabis ETF (NYSE: THCX) This simply named, easy-to-remember ETF currently has $16.66 million in AUM. It has a cookie-cutter set of holdings; its top three positions are almost identical to those of MJ (but with a smaller Cronos Group allocation and a larger Canopy Growth Corp. position). Its expense ratio of 0.70% makes it cheaper than any of the largest three ETFs. THCX does not pay a dividend and currently trades at a 0.50% premium to NAV. 40,278 shares have changed hands in the last month. Cambria Cannabis ETF (BATS: TOKE) The only pot stock ETF that trades on the BATS exchange, TOKE is one of the smaller members of the pack, with just $9.81 million in AUM. It has a fairly typical Canada-heavy set of holdings. MediPharm Labs Corporation (TSX: LABS), Aphria, and GW Pharmaceuticals round out the top three. It has an unusually low expense ratio of 0.42%. TOKE pays no dividend and currently trades for a 0.42% premium to NAV. Just 9,448 shares have changed hands in the last month. Purpose Marijuana Opportunities Fund (OTC: MRJOF) MJROF is one of two over-the-counter (OTC) pot stock ETFs we will discuss in this article. Its lack of exchange listing makes it somewhat difficult to find information about it, but it is a pot stock ETF that is on the market today, so it goes on this list. It has $8.33 million in AUM. The fund has an unusual set of holdings. Its top position isn’t actually a marijuana company but rather a Canadian cash-equivalent fund: the Purpose High-Interest Savings ETF (TSX: PSA). OrganiGram Holdings (TSX: OGI) and Curaleaf Holdings (CSE: CURA) round out the top three. MJROF charges a 0.75% expense ratio. It pays a 3.01% dividend and does not appear to publish information about its discount or premium to NAV or trading volume. Evolve Marijuana ETF (TSX: SEED) SEED is the smallest Toronto-listed pot stock ETF on this list, with just $6.942 million in AUM. It has an almost-entirely-Canadian set of holdings, led by Aurora, Canopy Growth, and Charlotte’s Web Holdings (TSX: CWEB). SEED charges a 1.13% expense ratio — the highest on this list. It pays no dividend and trades for an unusually high 1.22% premium to NAV. Just 2,379 shares have been traded in the last month, making SEED one of the lowest-volume pot stock ETFs. The #1 pot stock to own in America It provides a critical service every single company in America NEEDS before they can sell any marijuana, a THC-infused edible, or cannabis beverage. In fact, they’ll all be required to have this ONE thing because of federal law. [Click here for details.]( Amplify Seymour Cannabis ETF (NYSE: CNBS) CNBS is even smaller than TOKE. Its AUM comes to just $5.86 million. Its holdings are a typical Canadian-oriented mix of pot stocks, with GW Pharma, Canopy Growth, and Canaccord Genuity Group (TSX: CF) as the top three. The fund charges a 0.75% expense ratio. CNBS pays no dividend and currently trades at a 0.31% premium to NAV. Just 7,800 shares have been traded in the last 30 days. Global X Cannabis ETF (NASDAQ: POTX) The newest member of the pot stock ETF pack, POTX has just $3.632 million in AUM at the time of writing. That’s largely a consequence of the fact that it’s only a month old; its AUM will likely grow in the coming months as its well-known issuer attracts more funds. As we discussed earlier, POTX has a heavily Canadian set of holdings led by GW Pharma, Canopy Growth, and Aphria. It charges a 0.50% expense ratio, making it one of the cheaper funds discussed in this article. It pays no dividend and currently trades for a 0.77% premium to NAV. It is too young for volume data to be available at the time of writing. Horizons Emerging Marijuana Growers ETF (OTC: HZEMF) HZEMF is the other OTC pot stock ETF. It’s the smallest of the whole group, with a tiny $3.38 million in AUM. But it has an interesting and unique focus: As its name implies, HZEMF focuses on small, up-and-coming pot producers rather than the big Canadian players. To that end, it has an unusual and less-recognizable set of holdings that are mostly American companies. The top three are Cresco Labs (OTC: CRLBF), Harvest Health & Recreation (OTC: HRVSF), and Neptune Wellness Solutions (NASDAQ: NEPT). It charges a 0.85% expense ratio. HZEMF pays a relatively high 4.85% dividend. Premium/discount information is not available for it due to its small size. It’s also the least liquid pot stock ETF — no more than 204 shares have been traded in the last month. Which One Is the Best? Different pot stock ETFs excel in different ways — it’s hard to say that one is superior to the others. But for your convenience, we’ll break down the “best in category” list below. MJ is the biggest, most liquid, and most discounted by NAV. HMMJ pays the highest dividend. And TOKE is the cheapest by expense ratio. But here’s the disappointing thing about all of the pot stock ETFs: They’ve all had rather abysmal performances as of late. [pot stock ETF] Only seven of the 10 ETFs have extensive enough price histories to be graphed over the course of one month. And as you can see above, the best performer lost more than 9% in October. Indeed, the broad marijuana industry has been having a tough time for the last couple of years — but that doesn’t mean every pot stock is doing poorly. In fact, there’s incredible value to be found in certain standout marijuana companies — if you know where to look. Angel Investment Research analyst Alex Koyfman recently completed [a comprehensive report]( about one such marijuana value stock. This small firm trades for just a couple of dollars a share, but it has a wide moat and incredible growth prospects that could help it lead the pot stock recovery. [Read more here.]( Until next time, [Monica Savaglia] Samuel Taube Samuel Taube brings years of experience researching ETFs, cryptocurrencies, muni bonds, value stocks, and more to [Wealth Daily](. He has been writing for investment newsletters since 2013 and has penned articles accurately predicting financial market reactions to Brexit, the election of Donald Trump, and more. Samuel holds a degree in economics from the University of Maryland, and his investment approach focuses on finding undervalued assets at every point in the business cycle and then reaping big returns when they recover. To learn more about Samuel, [click here](. Enjoy reading this article? [Click here]( to like it and receive similar articles to read! Browse Our Archives [How to Make $11,600 a Month from Amazon]( [5G: What You Need to Know]( [It's All About Context]( [3 IPOs to Watch for in 2020]( [Wealth Daily's 2020 Market Outlook]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Wealth Daily, please add newsletter@wealthdaily.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Wealth Daily](, Copyright © 2019, [Angel Publishing LLC](. All rights reserved. 111 Market Place #720 Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Wealth Daily as well as a link to www.wealthdaily.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. [View our privacy policy here.]( No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Wealth Daily]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.